Key result
Concomitant AF ablation plus LAAO shows no increased 1-year mortality compared to LAAO alone.
Why the study?
Performing concomitant AF ablation and LAAO may improve efficiency, but evidence evaluating safety and concerns regarding periprocedural and longer-term complications remains limited.
Does concomitant atrial fibrillation ablation and left atrial appendage occlusion improve safety and outcomes compared to LAAO alone in adults with atrial fibrillation?
Cohort (n=3,798)
Yes
Does concomitant atrial fibrillation ablation and left atrial appendage occlusion improve safety and outcomes compared to LAAO alone in adults with atrial fibrillation?
Answers are grounded in this paper and cite their sources.
Performing atrial fibrillation ablation concomitantly with left atrial appendage occlusion is safe and does not increase the risk of early or 1-year complications compared to LAAO alone.
BACKGROUND: Performing atrial fibrillation (AF) catheter ablation and percutaneous left atrial appendage occlusion (LAAO) during a single procedure may improve efficiency and reduce cumulative procedural risk. However, concerns remain regarding potential increases in periprocedural and longer-term complications, including stroke, pericardial effusion, device leak, and device-related thrombus. Evidence evaluating the safety of this concomitant strategy remains limited. OBJECTIVES: The objectives of the study was to compare the safety and short- and long-term outcomes of concomitant AF ablation plus LAAO vs LAAO alone. METHODS: We conducted a retrospective cohort study using the TriNetX U.S. Collaborative Network, identifying adults (≥18 years) with AF who underwent percutaneous LAAO between January 2015 and February 2026. Patients undergoing AF ablation on the same day as LAAO were compared with those undergoing LAAO alone. After 1:1 propensity score matching for demographics, comorbidities, cardiovascular medications, and laboratory values, 1,899 patients were included in each group. Outcomes including all-cause mortality, stroke, device leak, device-related thrombus, pericardial effusion, and pericardiocentesis were assessed at 7 days, 90 days, and 1 year using cumulative incidence and Cox proportional hazards models. RESULTS: Baseline characteristics were well balanced after matching. Concomitant AF ablation was not associated with increased adverse events. Mortality was similar at 90 days (0.6% vs 0.6%; HR: 1.00; 95% CI: 0.43-2.32) and 1 year (1.4% vs 1.5%; HR: 0.97; 95% CI: 0.58-1.63). At 90 days, rates of stroke, device leak, and device-related thrombus were comparable between groups, with no differences observed at 1 year. CONCLUSIONS: In this large, propensity-matched analysis, concomitant AF ablation at the time of LAAO was not associated with increased early or 1-year complications, supporting the safety of a combined approach in appropriately selected patients.
No takes yet. Share an insight, caveat, or question.
Sawalha et al. (2026) conducted a cohort in Atrial fibrillation (n=3,798). Concomitant AF ablation plus LAAO vs. LAAO alone was evaluated on 1-year all-cause mortality (HR 0.97, 95% CI 0.58-1.63). Concomitant AF ablation plus LAAO was not associated with increased 1-year mortality compared to LAAO alone (1.4% vs 1.5%; HR 0.97; 95% CI 0.58-1.63).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: